ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
Year-over-year SG&A expense growth
3Y CAGR
-8.2%/yr
vs +94.4%/yr prior
Acceleration
-102.5pp
Decelerating
Percentile
P54
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 8.00% |
| Q3 2025 | -6.26% |
| Q2 2025 | 6.85% |
| Q1 2025 | 9.77% |
| Q4 2024 | -11.83% |
| Q3 2024 | 49.70% |
| Q2 2024 | 10.00% |
| Q1 2024 | 8.00% |
| Q4 2023 | 5.84% |
| Q3 2023 | 8.38% |
| Q2 2023 | 6.28% |
| Q1 2023 | 9.88% |
| Q4 2022 | 10.33% |
| Q3 2022 | -5.87% |
| Q2 2022 | 10.90% |
| Q1 2022 | -6.15% |
| Q4 2021 | 78.72% |
| Q3 2021 | -8.71% |
| Q2 2021 | 7.01% |
| Q1 2021 | 22.43% |
| Q4 2020 | -8.65% |
| Q3 2020 | -25.87% |
| Q2 2020 | 55.03% |
| Q1 2020 | -2.36% |
| Q4 2019 | -2.39% |
| Q3 2019 | 1.19% |
| Q2 2019 | 6.81% |
| Q1 2019 | -0.69% |
| Q4 2018 | 13.65% |
| Q3 2018 | 18.14% |
| Q2 2018 | 11.23% |
| Q1 2018 | 0.80% |
| Q4 2017 | 10.76% |
| Q3 2017 | 8.70% |
| Q2 2017 | 1.19% |
| Q1 2017 | -1.03% |
| Q4 2016 | 6.37% |
| Q3 2016 | -9.18% |
| Q2 2016 | 29.20% |
| Q1 2016 | 8.23% |